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Islam Eljilany, Faris El-Dahiyat, Louise Elizabeth Curley & Zaheer-Ud-Din Babar  
 
Objective: To evaluate the quality and quantity of health economic researches published until 
the end of 2017 in G.C.C. and to identify the factors that affect the quality of studies. 
 
Method: Studies were included according to predefined inclusion and exclusion criteria. The 
quantity was recorded, and the quality was assessed using the Quality of Health Economic 
Studies (QHES) instrument. 
 
Results: Forty-nine studies were included. The mean (SD) quality score of all studies was 57.83 
(25.05), and a high number of reviewed studies (47%) were evaluated as either poor or 
extremely poor quality. 
 
The factors that affect the quality of studies with statistical significance were, the type and 
method of economic evaluation, the economic outcome was the objective of the research, 
author`s background, the perspective of the study, health intervention and source of funding. 
 
Conclusion: The use of economic evaluation studies in G.C.C was limited. Different factors 
that affect the quality of articles such as performing a full economic evaluation and choosing 
societal perspective were identified. Strategies to improve the quality of future studies were 
recommended. 
 
KEYWORDS: Pharmacoeconomics, health economics, QHES, Gulf Cooperation Council, 
quality, quality of literature  
 
1. Introduction 
 
The importance of pharmacoeconomics and health economics has recently been highlighted. 
There has been an increase in published research in this field and a number of landmark 
publications, such as those done by Newhouse JP,1 Buxton MJ et al.2 and Cutler DM and Reber 
S.3. The utility of this research has also been realized, with the outcomes aiding optimal 
decision-making in medicines and medical services, ultimately improving cost-effective choices 
in the health sector .4 
However, despite the potential use of these publications, this depends substantially on the 
quality of the research. There have been concerns about the quality of some health economics 
studies published in the medical literature, with some published material being categorized as 
poor quality.5-7 Poor or inferior quality research not only is not helpful, but it provides 
confusion and casts doubt on other research, and thus it is imperative that studies are evaluated 
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for their ability to meet quality criteria.8 Pharmacoeconomics and health economics are relevant 
to all regions, including economically growing countries such as the Gulf Cooperation Council 
(G.C.C) countries. G.C.C countries are a group of countries that locate in the Middle East, 
overlooking the Arab Gulf Peninsula in a region of the largest oil producing area in the world. It 
consists of 6 countries that are similar in culture, habits, environment and economy. They are 
The Kingdom of Saudi Arabia (K.S.A), The United Arab Emirates (U.A.E), the State of 
Kuwait, The Sultanate of Oman, the State of Qatar and the State of Bahrain, with a total 
population of 47 million and a Gross Domestic Product (GDP) of 1.6 trillion, averaging to 33.3 
thousand dollar GDP per capita.9 
 The G.C.C has recently observed extraordinary growth in the GDP, if the  healthcare market 
alone is considered, there has been an annual rise at rate of 11% from approximately US$25.6 
billion in 2010 to US$43.9 billion in 2015.10 
While the role of the economic evaluation in decision-making in developed countries was 
established in the early 1970s, only recently have these practices started to be used in countries 
like the G.C.C. However, the importance of these practices has been known for some time, 
providing economic evidence in support of decisions on licensing, pricing, reimbursement and 
formulary additions.8  
To date, there has been no analyses conducted of the economic evaluation studies emerging 
from G.C.C, and there is still little information about the health and pharmacy economics 
studies in the region. Also, the current economic downward due to a reduction in Oil`s price and 
increasing population in the region so, it is imperative to evaluate the studies that originate in 
this region, for quantity and quality, in order to make future recommendations for research and 
to ensure that the studies being utilized for decision-making for medicines and medical services 
are based on sound evidence.  
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The present study’s objective aimed to evaluate the quality and quantity of health economic 
evaluations that are emerging from the G.C.C countries, published until the end of 2017. A 
comparative description of the studies characteristics was also conducted to identify factors 
affecting the quality of research in the future. 
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2. Methods 
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 
guidelines for conducting systematic reviews were employed.11 A literature search was carried 
out between September 2, 2017, and January 1, 2018, to identify all published health economics 
and pharmacoeconomics evaluation research from the countries of the G.C.C in English. The 
search was conducted in Pub Med and used the following index terms used in search were: 
“cost”, “budget”, “fee”, “health”, “pharmacy”, “economics”, “health economics”, 
“pharmacoeconomics”, “cost-effectiveness”, “cost-benefit”, “cost-utility”, “cost minimization” 
AND “Arabian Gulf countries”, “ Gulf cooperation council”, “G.C.C. countries”, “Saudi 
Arabia”, “KSA” , “United Arab of Emirates”, “UAE”, “Kuwait”, “Qatar”, “Bahrain”, “The 
Sultanate of Oman”, “Oman”. The index terms used were searched utilizing “AND” to combine 
keywords listed. References of retrieved articles were considered for relevant articles that may 
have been missed.  
2.1 Article selection and inclusion criteria  
The title and abstract of all retrieved articles were reviewed for relevance, if there were 
uncertainty about the papers; the full text article was retrieved and read for relevance. Research 
that was written in the English language and published up until the end of 2017 were included. 
Studies needed to specifically state that (one or more of) their aims/objectives were related to 
health-related economic analysis or cost analysis. The research should focus on health 
economics in one of the G.C.C countries and should be an original (Primary source) research 
article where the full text was available.
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2.2 Data Collection and Classification 
Each article was examined carefully, and detailed information about the journal and article were 
entered in defined data collection tool.  
Information about the journals in which each study was published was collected; journal’s 
location and scope of a journal if it is medical oriented or other such as health management, 
economic or business. The access of journal was classified into open access and paid journal. 
Extensive data about each published article were collected; the total number of authors, country 
and background of the first author information were obtained from the affiliation of each study, 
year of publication of study and the study period. Source of funding and location of study data 
was collected.The geographical location of the study was classified into sub-national, national 
and multinational. 
The detailed information regarding the economic analysis conducted in each study, was the 
method of economic evaluation clearly stated the objective, type of costs included, type of 
currency used. Articles were classified according to the perspective of economic information if 
it was reported or not. A perspective refers to the point of view from which an economic 
analysis is performed; the five most common perspectives that are often cited within 
pharmacoeconomic studies are: institutional, third party, patient, governmental or societal.12 
Furthermore, articles were categorized as full economic evaluation if they meet the 
requirements defined by Drummond et al.4; cost-effective analysis (CEA), cost-benefit analysis 
(CBA), cost-utility analysis (CUA) and cost-minimization analysis (CMA). Articles that did not 
meet Drummond et al. requirements were classified as partial economic evaluations; cost 
description (CD), cost analysis (CA) and cost of illness (COI). 
The primary health intervention discussed in the article was also examined. The health 
intervention of each study was classified into five categories according to the intervention 
covered in the study as health technology for new technology, public health if a disease and 
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healthcare expenditure were discussed, pharmaceutical if drug or molecule was covered, service 
if new or old service was assessed and surgery.  
 
2.3 Assessing the quality of the included article 
Quality of health economic studies instrument (QHES) was used as a grading system for quality 
of the studies included as previously described in Offman J et al.13 The QHES is a rating 
instrument that provides a score out of a maximum of 100 points based on 16 question criteria. 
The total points based on the criteria are then totalled, and a final score classifies each study 
according to 5 categories13; extremely poor (score ≤24), poor (25≤score<50), fair 
(50≤score≤74), good (75≤score<100) and excellent quality (score=100). 
 
2.4 Statistical analysis 
A mean of the quality scores for each study was calculated, and standard deviation (SD) was 
calculated across study characteristics. Descriptive statistics were used to measure the 
distribution of all variables and an independent t-test used to determine if there was a significant 
difference in the mean quality of studies by dichotomous variables (country of author, country 
of journal, scope of journal, type of economic evaluation, background or experience of first 
author, journal access and if economic evaluation was clearly stated in the objective). A one 
way Analysis of Variance (ANOVA) test was used to test the statistical significance of the 
difference in the mean quality of studies by variable had more than two categories (Perspective 
of study, the source of funding, a method of economic evaluation, country of study and primary 
health intervention). The Pearson correlation coefficient was used to determine the relationship 
between quality score and sample size, number of authors and publication’s year. All statistical 
analysis was performed using Statistical Package for the Social Sciences (SPSS) version 18. A 
p-value of <0.05 was considered statistically significant.  
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3. RESULTS 
 
 In total, the literature search identified 4066 articles as shown in table 1. After careful reading 
of the abstracts and titles, 992 were excluded due to duplication which yields 3074 articles. 
After a detailed examination of these articles 3025 studies were excluded, 1.4% of excluded 
studies were not full text (n=44), 2.1% of excluded studies were not an original study (n=64), 
57.7% of excluded studies were not economic evaluation analysis (n=1744), 22.7%  of excluded 
studies were not on G.C.C (n=688), 16% of excluded studies were not on health-related 
(n=484), and one excluded study was not in English (Figure 1). The articles included were 
retrieved solely from Pubmed database, although references for each included article were 
examined carefully to find any health economic or pharmacoeconomics literature from G.C.C., 
however, no additional articles were added. Finally, 49 published studies that met with 
inclusion criteria where included 14-62 (Table 2). 
 
3.1 Studies characteristics  
3.1.1 Publication characteristics  
The majority of studies (n= 34)  were published in international journals14,17-19,21,24,25,27-30,35-43,45-
48,50-54,57-61 and the remaining 15 studies were published in journals based in G.C.C. countries. 
15,16,20,22,23,26,31-34,44,49,55,56,62 Thirty seven studies were published in medical journals, 14-20,22-26,28-
33,36,38,40,41,44,46,49,50,52-62 7 in non-medical journals21,27,34,35,37,39,48 and only 5 studies were 
published in health/medical economics journals 42,43,45,47,51 (Table 3). Forty two studies 
published in open access journals 14,16,18-47,49-51,55-58,60-62 while 7 studies published in paid access 
journals 15,17,48,52-54,59 (Table 3). The earliest study was published in 199114 and the most recent 
study was published in December 2017.62 The majority studies were published in 2016 49-56 
(Figure 2). 
8 
 
 
3.1.2 Primary author characteristics 
The mean (SD) number of authors per study was 4.20 (2.97) (range,1-18), in 45 studies the 
main authors were residing in the same country of study14-24,26,28-32,36-59,61,62 and only in 4 studies 
the main authors were residing in countries outside the G.C.C. 25,27,35,60; these included Canada, 
25 USA ,27 UK35 and Poland.60 The primary author in 40 of the included studies (81.6%) had a  
medical or clinical background 14-24,26-30,32-34,36-47,49,51,53,55-59,61 , compared with 4 studies were 
the primary background was health economics 48,52,60,62, 3 studies were public health was the 
primary background35,50,54 and 2 studies were the primary background was of nonmedical 
origin.25, 31   
 
3.1.3 Geographical location of data collection 
Thirty four studies were national, 14,15,18-24,26,29-34,38-41,45-50,51-55,59-62 9 studies were sub-national 
(where they covered cities of interest in a country)16,28,36,42,44,50,56-58 and 6 studies were 
multinational.17, 25, 27,35,37,43  
Eighteen of the studies published were based on data from Saudi Arabia, 15,16,23,26,28,31,34,36,39,44, 
47,53,56-59,61,62 11 studies on data originating from Oman, 18-22,33,38,39,49,55 7 studies with data from 
the United Arab of Emirates,24,29,40,42,43,50,60 5 studies from Qatar, 30,45,488,52,54 3 studies were 
published on Kuwait 14,37,51 and one study published on Bahrain45 (Figure 3). 
 
3.1.4 Funding sources 
Thirty-four studies stated they did not receive any funding to conduct the research 14-17,19-23,26-
28,30-33,36,38-40,44-46,50,51,53,55-59,62 Six studies were funded by government organizations,18,24,34,35,37,41  
6 studies were funded by the pharmaceutical industry 25,29,42,47,60,61  and 3 studies were funded by 
non-profit organizations.48, 52,54  
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3.1.5 Condition characteristics 
The majority of studies (35[71.4%]) did not state the pharmacoeconomics perspective. 14-17,19,22-
37,39,41,43,45,49-51,53-59 Ten (20.4%) studies were from the provider perspective, 18,20,21,42,44,46,48,52,60,62  
3 studies (6%) were from the society perspective 38,40,61 and one study (2%) was from the patient 
perspective .47 Forty two (85.7%) studies were published in open access journals 14,16,18-47,49-51,55-
58,60-62 whilst 7 (14.3%) studies published in paid access journal 15,17,48,52-54,55 (Table 3).  
Twenty one studies did not investigate a specific disease. 14,16,17,19,20,23,26,28,33,35,39,41,43,45,49,52,53,55, 
56,59  Overall, 20 diseases were investigated over 27 studies. Diabetes 24,41,54,60 and rotavirus were 
investigated in 4 separate studies.21,25,38,61  Asthma was investigated in 2 studies. 32,42 Each of 
the following conditions were investigated by a single study: neonatal hip instability,15 
epilepsy,18  thyroid function,22 acute gastroenteritis,29 trauma,30 deep vein thrombosis,34 
uveitis,36 invasive aspergillosis,37 mitral valve disease,40 infection,44 acute tonsil pharyngitis,46 
osteoarthritis,47 hyperlipidemia,48 refractory chronic urticaria,51  heart failure,57 diabetic 
retinopathy,58 and mental health.60  
Nineteen studies focused on public health, 16,18,21,24,25,29-32,35,36,38,41-43,45,53,54,57 12 studies on 
services, 14,20,22,26,27,34,46,49,50,55,56,59 12 on pharmaceutical products, 17,20,23,39,44,47,48,51,52,60-62 5 on 
health technology 28,33,37,40,58 and one study on surgery. 15 
 
3.2 Trends in Economic Evaluation studies 
There were 40 partial 14-37,39,42,43,45,46,49-59 and 9 full economic studies; of the latter there were 4 
CEA,40,48,60,61 CBA,41 three CUA37,47,62  and one CMA.44  
The economic evaluation was stated clearly as a primary outcome in 37 studies 14, 15, 18-22, 24, 26, 
30-33, 35, 38-52, 54, 56-62 (Table 3).  
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3.3 Quality score of studies 
The mean (SD) quality score of all 49 studies was 57.83 (25.05) and ranged from 15 to 100. Six 
studies were of an extremely poor quality, 15,22,27,28,53,59 17 studies were classified as poor 
quality, 16,17,19,20,23,26,30,31,34,36,37,43,45,46,55,56,58 14 studies were of fair quality, 14,24,25,29,32,33,35,39-
42,49,50 9 studies were of good quality, 18,21,38,44,45,46,47,57,60 and 4 studies were scored as excellent 
quality.47,48,61,62 
 
3.4 Factors affecting the quality of studies  
3.4.1 Country of origin 
When country of origin was factored into the scoring, the mean (SD) quality score by country 
was Qatar 68.6 (24.42), U.A.E 66.42 (18.5), Kuwait 62 (33.4), Oman 60.09 (22.52), Saudi 
Arabia 53.16 (29.53), and Bahrain 43 (0). Summaries of the mean score as per countries are as 
shown in (Figure 4). There were no significant differences found when the scores were 
compared based on country of origin. 
3.4.2 Method of evaluation  
A higher quality score of studies was significantly associated (p<0.05) with the type of 
economic evaluation used (full evaluation was higher), whether economic outcomes were stated 
in primary objectives of the study (whereby if this was stated as a primary objective the 
resulting quality of the study was higher) and the method of economic evaluation used (CUA 
resulted in the highest quality studies).  
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3.4.3 Publication and author characteristics 
The quality of studies affected by the training of first author and the source of the funding but it 
was not affected by country of the journal, the scope of the journal, country of the author, or the 
number of authors. There was a positive correlation (r=0.276) between the number of authors 
and the quality of study as the number of authors increases, the quality of study was found to 
increase.  
A positive correlation was also shown with respect to year of publication (r=0.256), where the 
most recent studies had better scores than older studies. The only negative correlation (r=0.042) 
was seen in sample size and quality score (Table 3). 
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4. Discussion 
Research surrounding health economics is becoming more valued, and used to assist in 
decision-making in regards to health services, and thus quality and assurance of this data are 
paramount. This review was the first study to collectively examine the research on health 
economics that is originating from G.C.C countries. The primary objective was to assess the 
quantity, characteristics and quality of these studies and to provide recommendations for future 
research. The recommendations should help to inform future research that is emerging from 
G.C.C countries, in addition to any country that may be publishing such data.  
 
This review found several interesting findings in regards to the quantity and characteristics of 
the research that is being published on this topic. Firstly, the number of studies on health 
economics originating from G.C.C has increased with time, especially after 2007 and peaked in 
2016. This could be reflective of the increased importance of cost, cost of care, increase the 
prevalence of orphan diseases and increase the use of new expensive medicines and hence why 
it is of utmost importance moving forward to ensure quality studies are emerging. However, 
despite the increase in quantity, the number of studies published from this region is low when 
compared to other countries. Even when the absolute number of health economic evaluation 
studies based in Saudi Arabia (which has the highest number in G.C.C.) was compared with 
studies centered in the United Kingdom, Australia, the United States, and Canada, where 
economic analyses are formally used in health policy formulation, the numbers were still 
low.4,63-66 The number was low even when compared to studies published in other developing 
countries, such as Korea (n = 45),67  Zimbabwe (n=26)68,  Thailand (n = 41)69  and Nigeria (n = 
44).70  In addition, there was a lack of studies focusing on pharmaceutical products (24.5%). 
These findings reflect the use of economic evaluation studies in decision-making in the region, 
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and these results of this review call for more research to be conducted in this region. However, 
this may reflect there is no requirement for submission economic data as a part of drug 
regulatory process in all countries of G.C.C, and thus in order for there to be a larger focus on 
this topic, change at a policy level may be required.  
 
Despite this literature review being based in G.C.C. countries, most of the studies were 
published in international journals, based outside the region. This may reflect the absence of 
well-established journals in the G.C.C. region, especially in health. However, this trend in 
publication may have a negative implication, as many people in G.C.C countries may not have 
access to these international journals.  This finding was found to a lesser extent in Saudi Arabia 
and Oman where many of their studies were published in journals of the same country.  
 
Another major finding of this study was the high degree of poor quality research that has been 
published, based on the criteria of the QHES tool. In this current review, the majority of 
reviewed studies (47%) were poor and extremely poor quality and only 18% were good quality 
and 6% were excellent quality. These findings are in line with the results of research by Walker 
and Fox-Rushby 71 and Lee et al, 67 who also found a limited supply of good quality economic 
evaluation studies in developing countries. Based on the small number of publications found, it 
appears that health policies and plans in G.C.C are being made without sound economic 
evaluation data, which confirms findings by Maynard.72 This is not a problem isolated to 
developing countries; Adams et al.5 evaluated completeness of economic analysis in 
randomized clinical trials that published in the United States. The findings from this research 
were that the mean quality score of published trials was 0.32 on a scale of 0 to 1. Moreover, 
Udvarhelyi et al6 explored whether published research using CEA and CUA in the United States 
adhered to basic analytic principles; the study found that the overall performance was only fair. 
14 
 
Lastly, Gerard K7 was validating the potential benefit in policy terms of studies that have used 
CUA in the United Kingdom, and results revealed studies’ technical execution was often of 
poor quality. 
 
Most of the reviewed studies in this review were partial economic evaluations; this may reflect 
the lack of experience of economic studies in the region. Partial economic evaluation measures 
the program or disease cost, but does not involve a comparison with alternative options and 
does not relate costs to outcomes.4 The COI was the most frequently used type (40%) of partial 
economic analysis used. Only 18% of studies conducted a full economic evaluation and 12% of 
studies used modeling techniques in the analysis. The CEA was the most frequently used 
method in the full economic evaluation analyses conducted within this review. Similarly, 
Teerawattananon et al.69 in Thailand found that CEA was the most popular (full economic) 
study type in Thailand and Lee et al. in Korea.67  
 
The quality of studies was significantly affected by seven publication factors; firstly, the type of 
economic evaluation used, studies with a full economic evaluation were statistically better 
quality. Secondly, when the primary objective of the study was economic evaluation, the 
research also achieved a statistically higher quality score. Thirdly, the QHES was statically 
significant with the method of economic evaluation used, whereby the highest score was 
achieved in the studies that applied CUA and CEA methods in their analyses. Fourthly, the 
background or experience of the primary author as studies whose primary author`s background 
was in health economics or public health achieved a statistically higher score, and this finding 
could be due to people with health economic background are more skillful in designing 
economic analysis. Fifthly, quality of studies was statistically significant with the perspective of 
the study where studies were done from a societal perspective were statistically better in quality, 
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the reason behind that could be; social perspective a wide financial perspective which takes into 
account all alternative of resources. Sixthly, when the health intervention was a pharmaceutical, 
the quality of studies was statistically the best due to most of the pharmaceutical intervention 
studies are conducted by pharmaceutical companies who are recruited expertise in economic 
evaluation. Lastly, the source of funding has a significant impact on the quality of studies, as 
studies were funded by non-profit organization achieved better quality than were self-funded, 
government or pharmaceutical companies.  
 
However, the quality of studies was not affected significantly by the scope of the journal, 
contrary to what was reported by Neumann et al.73 and Gerard K,74 who found that medical 
journals have a higher chance of publishing poor quality studies. 
 
It is clear that Qatar had the highest mean of the quality score, but this could be due to it has a 
small number of studies including the research by Al-Badriyeh D et al.48 whose study is one of 
four studies that got 100 points on the quality score. 
 
Also it must be mentioned that there is a possibility of conflict of interest in some included 
studies as they received funding from pharmaceutical companies such as Merk & Co,25 Merk 
Sharp and Dohme (MSD),29 GlaxoSmithKline (GSK),42,61 Pfizer47 and Janssen Pharmaceutical 
NV.60 Qatar Foundation was the only nonprofit organisation which supported three studies.48, 
52,54  
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5. Recommendations 
Increase health costs and spending in G.C.C provide an urgent impetus for high quality and 
good quantity of health economic research emerging from the G.C.C to help decision maker to 
take a valuable decision in health resource allocation. This study has found that there is a great 
need for improvement in both the quantity and quality of economic evaluation analysis in 
G.C.C. 
 
There are several strategies that can be implemented to improve quality of evaluations 
originating from this (and other) region. For example, incorporation of health economics or 
pharmacoeconomics expertise in the research team will have an impact on designing good 
quality studies. Moreover, setting economic evaluation as a primary objective of the research 
and using the full economic evaluation type, especially CUA or CEA as the method of analysis. 
Thinking more laterally, an example is to increase education of the topic of health economics 
and pharmacoeconomics in the undergraduate and postgraduate courses. Increasing knowledge 
surrounding the most appropriate methodology and practice to conduct these analyses will 
without any doubt improve understanding by future researchers.  
Furthermore, by ensuring that cost-effectiveness studies were one of the requirements for 
registration of medicines or medical services for enlisting them in national health insurance this 
should have a positive effect the in development of economic evaluation in G.C.C. countries. 
This change could emphasize the need and importance of these evaluations in the decision-
making process.  
Finally, by establishing health economics and pharmacoeconomics department in governmental 
health authorities, national health insurance and government hospitals will allow these 
organizations to conduct economic evaluation studies as a part of the usual process. It is 
important if this is to occur to use established methodological guidelines and processes that will 
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help standardise future economic analyses. Ultimately, these factors will aid in establishing 
standardised unified pharmacoeconomic guidelines and legislation by G.C.C. 
 
 
6. Limitations  
This study has some limitations. The search was conducted in one database (Pub Med) which 
can increase the chance of missing published articles, however, to combat these reference lists 
were examined to ensure that other relevant studies were identified. Furthermore, some articles 
did not obviously describe their methods, which made it is difficult to categorize outcomes. 
 
7. Conclusion   
 
The number of economic evaluation studies in the period between 1991 and end of 2017 was 
limited in G.C.C countries. Many of the studies that have been published are of poor quality; 
this quality can be improved by Incorporation of health economics or pharmacoeconomics 
expertise in the research team and performing a full economic evaluation and choosing either 
CUA or CEA as the economic evaluation method. In addition, economic outcomes should be 
one of the primary objectives of the nstudy and analysis should be from societal perspective . 
Actions need to be taken to improve quality and quantity of pharmacoeconomics analysis and 
health outcome research and to promote the use of health economics discipline in decision-
making policy, registration and reimbursement of medicines in this region. 
 
 
 
 
 
8. Key Issues 
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         This study to evaluate the quality and quantity of health economic research 
published in Gulf Cooperation Council countries till 31-12-2017. 
         The majority of Pharmacoeconomic/ Health economic researches in Gulf 
Cooperation Council countries were poor and extremely poor in quality based on 
Quality of Health Economic Studies instrument (QHES). 
         Main factors that influence the quality of Pharmacoeconomic/ Health 
economic researches were identified. 
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Table 1: Number of search results by key term without duplication  
20 
 
 
Table 2: Articles included in the present study (n=49)  
Study (First 
author`s name) 
QHES The conclusion of included studies 
Method of economic 
evaluation 
Baraka A, et al.14 68 Cross-matching blood by the technicians contributed to 54.4% of the total working hours. 
This reflected a yearly loss of 25000.00 USD  
CD 
Al-Umran K.15 15 Cost-effectiveness of running a diagnostic program for CDH was found.  CD 
Al-Dawood 
KM.16 
36 In 1995  occupational injuries equated to 18.3% of total injuries reported. This led to high 
cost of medical fees, human suffering and a decrease in productivity.   
COI 
Abou-Auda 
HS.17 
41 The cost of unused medicines in KSA and other Gulf countries was US$150 million  CD 
Al Zakwani I, et 
al.18 
77 The newer drugs contribute to a high degree of total cost and therefore their additional  
benefit needs to be vigourously assessed. 
COI 
Al Khabori M, 
etal.19 
44 Ear care guidelines should take into consideration how earwax can affect hearing 
difficulties and put a strain on resources. 
COI 
Key term 
Arabian 
Gulf 
countries 
Gulf 
cooperation 
council 
G.C.C. 
countries 
Saudi 
Arabia 
KSA 
United 
Arab of 
Emirates 
UAE Kuwait Qatar Bahrain 
The 
Sultanate of 
Oman 
Oman 
Cost 
17 19 0 60 40 81 6 71 153 35 16 45 
Budget 
1 1 1 10 5 2 0 10 4 6 1 4 
Fee 0 3 0 40 25 1 0 8 87 13 8 35 
Health 80 51 1 100 49 569 124 88 95 151 159 185 
Pharmacy 6 7 1 22 22 146 3 45 22 15 16 50 
Economics 8 14 0 4 2 8 1 11 1 1 0 0 
Health economics 6 12 0 15 7 6 0 7 0 1 0 0 
Pharmacoeconomics 1 0 0 3 2 2 0 5 2 0 0 0 
Cost-effectiveness 1 1 0 41 21 2 0 2 7 3 0 9 
Cost-benefit 
0 2 0 10 3 3 0 16 6 0 0 1 
Cost-utility 
0 0 0 5 1 0 0 1 2 0 0 0 
Cost minimization 
0 0 0 2 0 0 0 1 0 0 0 0 
Total 
120 110 3 312 
177 
820 134 265 379 225 200 329 
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Al-Siyabi K, et 
al.20 
46 In Oman patients were requested to return any medication that was not used by them. The 
total sum equated to 20,140 Omani Riyal. Most of these medications were for 
cardiovascular or infectious diseases, which were also the most expensive medications 
CA 
Al Awaidy SA, 
et al.21 
84 A vaccination programme may substantially reduce the cost spent on treating rotovirus in 
Oman, the study showed that the total cost spent by the Omani government was US791,817 
annually in outpatient and US$1.8million in outpatient and hospital settings, respectively.  
COI 
El Shafie K, et 
al.22 
21 In patients presenting with neck swelling, thyroid function tests are necessary. Restraint 
should be used in those with just fatigue or palpitations.  
CD 
Alsultan MS, et 
al.23 
38 A waste of resources was evident in terms of IV PPI use in patients in the non-ICU setting, 
receiving treatment for stress-ulcer prevention for these patients, which as a result put a 
burden on the total budget of the health .  
CA 
Al-Maskari F, et 
al.24 
71 Healthcare resources to reduce the impact of DM, including DM care guidelines, screening 
for complications and better management may assist in reducing the cost. This study found 
that the cost of DM was heightened in disease progression with complications, and a large 
proportion of this cost was due to hospitalisations.  
COI 
Khoury H, et 
al.25 
52 A vaccination programme may substantially reduce the cost spent on treating rotavirus in 
the Middle East and North Africa This vaccine must have a broad and consistent serotype 
coverage to account for the variety of strains seen in these regions. 
COI 
Study (First 
author`s name) 
QHES The conclusion of included studies 
Method of economic 
evaluation 
Al Saran 
K, Sabry A.26 
42 KSA shows that the treatment cost for a hemodialysis patient is below the cost in the 
industrialized world. 
COI 
Khaliq AA.27 21 Saudi Arabia is fronting obstacles in many different aspects so they can manage to develop 
a successful health care infrastructure which is not unique .this can be accomplished by 
implementing strategies that can lead them to accomplish their target. 
CD 
Alameddine 
M, Nassir A.28 
24 Urine Cytology test shouldn’t be used as a diagnostic strategy for Urothelial cancer patients 
except in certain conditions. 
CD 
Howidi M, et 
al.29 
74 Children who are below five years old and acquired gastroenteraitis  affected their parents 
on a productivity scale causing at least one day off and an average loss of $64 USD. 
COI 
Tuma MA, et 
al.30 
42 Occupational injuries happening on construction sites such as falling from height is the 
most crucial source of trauma, which causes a high weight on the health care system 
budget. 
COI 
22 
 
Alhowaish AK, 
et al.31 
43 The forecasted cost for the national healthcare for DM is going to exceed US$0.87 billion 
including both direct and indirect costs  
COI 
Al-Busaidi NH, 
et al.32 
70 MOH expenditure for asthma medications is considered low compared to the high 
expenditure for inpatient and emergency visits Better asthma control can correlate with a 
positive impact on the total expenditure for the MOH.  
COI 
Khan SY, et al.33 64 The study suggests that laparoscopic surgery is more expensive versus open-
appendectomies, but it is still safe and doesn’t rise the morbidity nor the hospitalization 
time. 
CA 
Algahtani F, et 
al.34 
46 Low molecular weight heparin to treat deep vein thrombosis aree cost effective and provide 
no difference in outcomes.   
CA 
Alkhamis A, et 
al.35 
65 Health finance reform in GCC countries could substantially improve the efficicency and 
equitable nature of spending in healthcare services, and may reduce out of pocket spending.  
CD 
Bawazeer AM, et 
al.36 
42 Only 2 of the whole patients with Anterior uveitis were Human leukocyte antigen B27 
presented in the study. taking into consideration that Human leukocyte antigen B27 cost is 
around 1000 Saudi riyal, so requesting Human leukocyte antigen B27 test for all uveitis 
patients seems not to be cost effective 
 
 
CD 
Study (First 
author`s name) 
QHES The conclusion of included studies 
Method of economic 
evaluation 
Ahmad S, et al.37 26 PCR assay’s based method for identifying (34-Bp tandem repeat/L98H) mutations is easy 
to run, available in most laboratories, with short processing time and low cost.  
CD 
Al Awaidy ST, 
et al.38 
97 Pentavalent Rotavirus vaccination has a significant impact on lowering of Rotavirus 
Gastrointestinal disease burden in Oman. This intervention is cost effective from both 
payer prospective and societal prospective. Application of universal vaccination will 
reduce parental work loss resulted from Rotavirus gastroenteritis attacks in children. 
CUA 
Al Balushi K, et 
al.39 
50 Oman emergency department drug prescribing behavior showed that Non-steroidal anti-
inflammatory drugs were the most prescribed followed by cardiovascular disease 
medication, then respiratory and finally gastrointestinal. The highest expenditure for a drug 
class was Anti-Infective drugs. 
CD 
Mihaljevic T, et 
al.40 
63 Although Robotically assisted metal valve repair surgery’s cost is considered high, it still 
offers lowest postoperative cost, fastest return to work, and high clinical benefit. To be cost 
effective this procedure should be applied in volume centers.  
CEA 
23 
 
Al-Qadhi W, et 
al.41 
62 Patient health questionnaire (PHQ2 and PHQ9 were equivocal) as a screening instrument 
for depression and their use in primary care  has cost saving potential.  
CD 
Alzaabi A, et 
al.42 
72 Due to the reported cases of asthma in Abu Dhabi in the emergency departments and the 
subsequent high expenditure there is a high burden on the healthcare budget. This data also 
indicates that asthma is not adequately controlled.,  
COI 
Hamidi S.43 32 This study suggests that there is an area of improvement in health policies in Abu Dhabi 
through switching from inpatient care to outpatient home care service and day surgery. 
Implementing cost constrain measures for pharmaceuticals. Finally focusing and funding of 
preventive care instead of curative care.    
CD 
Joosub I, et al.44 97 Mean total costs per day were not significantly different between imipenem/cilastatin  and 
meropenem, which implies that the overall cost of treating moderate to severe infections is 
only affected to a small degree by the medications.  
CMA 
Al-Kaabi SK, et 
al.45 
49 Gulf Cooperation Council expenditure for managing non-communicable diseases 
(cardiovascular disease, mental health, behavioral disorders, cancer, respiratory disease, 
and diabetes) was above the official targeted expenditure .The total bill for all these 
diseases were US$36.2 Billion. 
COI 
Study (First 
author`s name) 
QHES The conclusion of included studies 
Method of economic 
evaluation 
Al Alawi S, et 
al.46 
43 Using Ceftriaxone in the Out Patient clinic in Bahrain for treating Acute 
Tonsillopharyngitis is considered safe, clinically effective ,and cost effective, with 
minimum Side effects and readmissions  
CA 
Nasef SA, et al.47 100 Osteoarthritis Patients who are above 65 years treated with Celecoxib with/without PPI co-
therapy was found to be highly cost effective for medium and long term usage. 
CUA 
Al-Badriyeh D, 
et al.48 
100 The study suggests that  the dyslipidemic medications atorvastatin and pravastatin should 
be used as a first line therapy, while rosuvastatin to be used as an alternative option  
CEA 
Akhwand S, et 
al.49 
71 Institutional ‘Do Not Resuscitate’ (DNR)  policies may help to reduce healthcare costs and 
improve services. However, these need to be used with a careful assessment. 
CD 
Hamidi S, et al.50 60 Neuropsychiatric services were only covered in 18% of the insurance plan in Abu Dhabi. 
Out of this 18%, 33% were fully covered and 67% were required to co-pay .It is suggested 
that basic insurance plans should fully cover neuropsychiatric services.  
CA 
Al-Ahmad M, et 
al.51 
92 Though omalizumab cost is high, it reduces Emergency and Outpatient cost due to its 
clinical effectiveness. In addition because it’s safe, it will be more economic effective if it 
was self-administrated at home.  
COI 
24 
 
Al-Badriyeh D, 
et al.52 
86 Based on evidence of the multi indication PPI Scoring model. It was found that 
esomeprazole and rabeprazole are preferred as a first line treatment in Qatari government 
hospitals and this has the potential of lowering the hospital PPI expenditure by 15%. 
CA 
Maraiki F, et al.53 18 Using Plastic Bags for I.V mixture provide a benefit over I.V glass bottle which may 
reduce the cost without affecting the drug stability. 
CA 
Bener A, et al.54 66 The burden of diabetes in Qatar is larger than expected by International Diabetes 
foundation. Medication and diabetes mellitus complication is the  main contributor of the 
cost. The increasing obesity with diabetes prevalence and need for medical treatment will 
drastically pressure the health budget.  
COI 
Islam SS, et al.55 37 The rate of Computed tomography increased by 67% between 2010 and 2014, which 
reflected on an up rise in the emergency department expenditure and a higher waiting time. 
CA 
Alawi MM, et 
al.56 
46 A stewardship program for prescribing antimicrobial showed high safety, clinical and cost-
effective as a preventive measure against Multi drug resistant infections.  
CA 
 
 
Study (First 
author`s name) 
QHES The conclusion of included studies 
Method of economic 
evaluation 
Salem K, et al.57 79 Congestive heart failure with reduced ejection fraction puts a large economic and disability 
load on one non-Organization for Economic Cooperation and Development Middle Eastern 
countries.  
COI 
Al-Otaibi H, et 
al.58 
48 RETeval Screening device could be the first device to distinguish patients that require 
further investigation for high threating diabetic retinopathy due to its outstanding 
sensitivity. 
CA 
Hindawi S, et 
al.59 
21 This study showed a deviation from the current policy instructing Universal testing and 
switching it to a Universal Leukodepletion with exception to donors from endemic or risky 
donors. This outcome due to the fact no donor was confirmed with a Human T-cell 
lymphotropic virus type1 and type 2 (HTLV1-HTLV2) from a pool of donors. If this is 
applied this will reduce the cost of tests without hindering the safety.   
CD 
Schubert A, et 
al.60 
93 Treating with Canagliflozin 100mg /300mg is more clinically and cost effective when 
compared with Dapagliflozin 10 mg or Empagliflozin 10mg/25mg in a patient with type 2 
diabetes mellitus.    
CEA 
25 
 
Al-Aidaroos AY, 
et al.61 
100 The Current Rotavirus vaccination is estimated to reduce the overall Rotavirus 
gastroenteritis burden by 65% over a life time with a reduction in outpatient and 
emergency visits by 87%. Cost neutrality is achieved if the price of vaccine per course is 
less than SAR 178.20. 
CEA 
Alsaqa’aby 
MF, et al.62 
100 All disease-modifying drugs included in the study were not cost effective in treatment 
relapsing-remitting multiple sclerosis at willing to pay threshold $100,000, and the 
threshold should reach $300,000 to be cost-effective. 
CUA 
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Table 3: Quality score and its relation to study characteristics  
Study characteristics No. Studies Mean of QHES SD (P-Value)Statistical test 
Country of journal 
   
(0.241) independent t-test 
Same country of study 15 51.46 24.56  
Outside the country 34 60.64 25.1  
Scope of journal 
   
(0.574) independent t-test 
Medical 37 56.67 24.2  
Other 12 61.41 28.32  
Country of the first Author 
   
(0.994) independent t-test 
Same country of study 45 57.96 25.97  
Outside 4 57.75 29.88  
Background or experience of the first author 
   
(0.032)** independent t-test 
Medical 40 54.22 24.61  
Other 9 73.88 21.33  
Geographic location of the study 
   
 
Sub national 9 56 23.09  
national 34 61.55 25.78  
multinational 6 39.5 16.67  
Country 
   
(0.702) One way ANOVA 
G.C.C. 4 44.75 18.62  
Bahrain 1 43 0  
Kuwait 3 62 33.4  
Qatar 5 68.6 24.42  
Saudi 18 53.16 29.53  
UAE 7 66.42 18.5  
Oman 11 60.09 22.52  
Source of funding 
   
(0.008)** One way ANOVA 
Government 6 57.83 28.77  
Pharmaceutical 6 81.83 19.14  
No fund 34 51.29 23.98  
Nonprofit organization 3 84 13.95  
Study perspective 
   
(0.00)** One way ANOVA 
Provider 10 79.8 20.03  
society 3 86.66 20.55  
Patient 1 100 0  
Study characteristics No. Studies Mean of QHES SD (P-Value)Statistical test 
27 
 
Not stated 35 47.88 19.4  
Method of economic evaluation 
   
(0.000)** One way ANOVA 
CBA 1 62 0  
CEA 4 89 17.64  
CUA 3 99 1.73  
CMA 1 97 0  
COI 16 62.06 17.76  
CD 13 38.23 19.7  
CA 11 48.36 17.32  
Type of economic evolution 
   
(0.000)** independent t-test 
Full 9 90.22 15.88  
Partial 40 50.55 20.59  
Was economic evaluation stated in objective? 
   
(0.001)** independent t-test 
yes 37 64.29 24.26  
no 12 37.91 15.41  
Health intervention 
   
(0.001)** One way ANOVA 
Health technology 5 45 19.33  
Public health 19 59.52 20.39  
Pharmaceutical 12 78.53 26.2  
Service 12 43.33 17.06  
Surgery 1 15 0  
Journal Access 
   
(0.351) independent t-test 
Opened access 42 59.21 23.34  
Paid access 7 49.57 34.69  
Sample size 
   
(0.779) Pearson Correlation 
Listed 40 57.62 25.11  
Not listed 9 58.77 26.23  
Pearson Correlation, r 
   
-0.042 
Number of authors 
   
(0.055) Pearson Correlation 
less than 5 32 52.12 23.71  
More than or equal 5 17 64.82 26.71  
Pearson Correlation, r 
   
0.276 
Year of Publication 49 57.83 25.05 (0.076) Pearson Correlation 
Pearson Correlation, r 
   
0.256 
Lowest QHES=15 and highest QHES=100          **p<0.05  
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Figure 1: Study selection flow diagram (based on PRISMA guidelines). 
 
  
Number of potentially appropriate 
articles identified through database 
searching (n=4066) 
Articles retrieved for more detailed 
analysis (n=3074) 
Total number of articles for final 
review (n=3074) 
Number of included articles (n=49) 
Excluded studies based on 
duplication (n=992) 
Studies obtained from 
references (n=0) 
Number of articles excluded from 
study inclusion/exclusion criteria 
(n=3025) 
Reason 
Excluded as they are not economic 
evaluation analysis (n=1744) 
Excluded as they are not on G.C.C. 
(n=688) 
Excluded as they are not on health 
related (n=484) 
Excluded because they are not an 
original study (n=64) 
Excluded as they are not full text 
(n=44) 
Excluded as they are not in English 
related (n=1) 
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Figure 2: Number of published studies per year       
 
 
Figure 3: The Proportion of studies of each country in the total included studies 
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Figure 4: Summery of mean QHES per country  
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Appendix 
Quality of health economic studies instrument (QHES) 
Question  Point  Yes  No 
1 Was the study objective presented in a clear, specific, and measurable manner?  7     
2 Was the perspective of the analysis (societal, third-party payer, etc.) and reasons for its selection 
stated? 
 4     
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3 Were variable estimates used in the analysis from the best available source (i.e., Randomized 
Controlled 
Trial – Best, Expert Opinion- Worst)? 
 8     
4 If estimates came from a subgroup analysis, were the groups pre specified at the beginning of the 
study? 
 1     
5 Was uncertainty handled by: 1) statistical analysis to address random events; 2) sensitivity analysis to 
cover a range of assumptions? 
 
 
9     
6 Was incremental analysis performed between alternatives for resources and costs?  6     
7 Was the methodology for data abstraction (including the value of health states and other benefits) 
stated? 
 
 
5     
8 Did the analytic horizon allow time for all relevant and important outcomes? Were benefits and costs 
that went beyond 1 year discounted (3-5%) and justification given for the discount rate? 
 
 
7     
9 Was the measurement of costs appropriate and the methodology for the estimation of quantities and 
unit costs clearly described? 
 
 
8     
10 Were the primary outcome measure(s) for the economic evaluation clearly stated and did they include 
the major short-term, long-term and negative outcomes? 
 
 
6     
11 Were the health outcome(s) measures/scales valid and reliable? If previously tested valid and reliable 
measures were not available, was justification given for the measures/scales used? 
 
 
7     
12 Were the economic model (including structure), study methods and analysis, and the components of 
the numerator and denominator displayed in a clear, transparent manner? 
 
 
8     
13 Were the choice of economic model, main assumptions and limitations of the study stated and 
justified? 
 7     
14 Did the author(s) explicitly discuss direction and magnitude of potential biases?  6     
15 Were the conclusions/recommendations of the study justified and based on the study results?  8     
16 Was there a statement disclosing the source of funding for the study?  3     
            Total points  100     
Source: Offman J et al. (2003) 13 
